Valuation: Exelixis, Inc.

Market Cap 17.51B 15.63B 14.38B 13.05B 24.73B 1,641B 25.34B 172B 68.55B 878B 65.7B 64.3B 2,767B P/E 2026 *
20.9x
P/E 2027 * 17.6x
Enterprise Value 16.56B 14.78B 13.6B 12.35B 23.4B 1,552B 23.98B 163B 64.86B 831B 62.16B 60.83B 2,618B EV / Sales 2026 *
6.48x
EV / Sales 2027 * 5.48x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day+3.12%
1 week+2.30%
Current month+3.39%
1 month+19.85%
3 months+32.68%
6 months+48.96%
Current year+63.68%
1 week 68.01
Extreme 68.01
73.69
1 month 58.59
Extreme 58.59
73.69
Current year 39.71
Extreme 39.71
73.69
1 year 39.71
Extreme 39.71
73.69
3 years 19.2
Extreme 19.2
73.69
5 years 14.87
Extreme 14.87
73.69
10 years 13.42
Extreme 13.42
73.69
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+3.12%+2.30%+75.79%+241.29% 17.51B
+2.24%+8.40%+58.47%+69.00% 68.22B
+0.89%+9.18%+15.57%+89.57% 59.82B
+0.49%+1.47%+23.93%+97.79% 56.07B
+2.55%+15.52%+30.43%+120.17% 47.67B
+2.58%+7.89%+32.49%+45.30% 45.95B
+4.09%+6.37%+228.06%+899.75% 43.29B
-0.47%+9.38%+27.53%+52.40% 35.66B
+0.38%-0.97%+96.37%+71.06% 34.73B
+1.48%+6.21%-38.80%+395.73% 25.47B
Average +1.12%+6.96%+54.98%+208.21% 43B
Weighted average by Cap. +1.20%+7.61%+54.66%+186.35%

Financials

2026 *2027 *
Net sales 2.56B 2.28B 2.1B 1.9B 3.61B 240B 3.7B 25.11B 10.01B 128B 9.59B 9.39B 404B 2.88B 2.57B 2.36B 2.14B 4.06B 270B 4.16B 28.26B 11.26B 144B 10.8B 10.57B 455B
Net income 895M 799M 735M 667M 1.26B 83.89B 1.3B 8.79B 3.51B 44.91B 3.36B 3.29B 141B 1.02B 912M 839M 761M 1.44B 95.74B 1.48B 10.04B 4B 51.26B 3.83B 3.75B 161B
Net Debt -943M -842M -775M -703M -1.33B -88.41B -1.37B -9.27B -3.69B -47.33B -3.54B -3.46B -149B -1.74B -1.55B -1.43B -1.3B -2.46B -163B -2.52B -17.11B -6.82B -87.37B -6.54B -6.4B -275B
Projected Income Statement - Annual - Exelixis, Inc.
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-11-10 $71.93 +0.26% 78,432
26-11-09 $71.74 +3.12% 4,826,248
26-11-06 $69.57 +1.25% 2,003,609
26-11-05 $68.71 -5.55% 4,376,151
26-11-04 $72.75 +0.61% 3,014,149
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Exelixis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
71.74USD
Average target price
61.57USD
Spread / Average Target
-14.17%
  1. Stock Market
  2. Stocks
  3. EXEL Stock